Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer

We conducted a phase II study of docetaxel in combination with everolimus, a mammalian target of rapamycin (mTOR) inhibitor, for salvage therapy of advanced non–small-cell lung cancer (NSCLC) based on promising preclinical and early-phase clinical data. Patients with advanced-stage NSCLC treated wit...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ramalingam, Suresh S., Owonikoko, Taofeek K., Behera, Madhusmita, Subramanian, Janakiraman, Saba, Nabil F., Kono, Scott A., Gal, Anthony A., Sica, Gabriel, Harvey, R. Donald, Chen, Zhengjia, Klass, Carmen M., Shin, Dong M., Fu, Haian, Sun, Shi-yong R., Govindan, Ramaswamy, Khuri, Fadlo R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4126230/
https://ncbi.nlm.nih.gov/pubmed/23407561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318282709c
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi